Keywords

antibodies, chronic liver disease, cirrhosis, direct-acting antivirals (DAAs), elastography, fibrosis, hepatitis C virus (HCV)

Authors

1. Pozza, Renee PhD, RN, FNP-BC, FAASLD
2. McCoy-Hill, Catherine DNP, CCRN, ANP
3. Hall, Katherine PhD, RN, FNP-BC
4. Hefner, Anna PhD, RN, CPNP
5. Wilgers, Kimberly BS, CMA
6. Tapelband, Julia BS, EMT
7. Masroor, Momin BS, EMT
8. Hassanein, Tarek MD, FACP, FACG, AGAF, FAASLD

Abstract

Abstract: Chronic hepatitis C virus (HCV) infection is a leading cause of liver disease. The World Health Organization has called for the global elimination of HCV by 2030. NPs can significantly expand the availability of community-based providers and bridge gaps in HCV treatment to assist in eradicating this curable virus.